Please ensure Javascript is enabled for purposes of website accessibility

This News Explains TransEnterix's Surging Share Price

By Brian Feroldi - May 29, 2018 at 9:54AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The good times continue for the robotic surgery upstart.

What happened

After announcing positive regulatory news, shares of TransEnterix (ASXC -4.04%), a medical device company focused on robotic surgery, soared 13% as of 9:57 a.m. EDT Tuesday.

So what

TransEnterix announced that it has received FDA clearance for a number of label expansion claims for its Senhance Surgical System. Specifically, the device can now be used for laparoscopic inguinal hernia and laparoscopic cholecystectomy surgeries.

A silhouette of a bull on a pice of paper with lists of numbers.

Image source: Getty Images.

The company estimates that this label expansion claim will widen its addressable market opportunity by nearly 2 million procedures annually. That represents a more than doubling of its current opportunity.

Here's what TransEnterix's CEO Todd Pope had to say about the approval:

"This indication expansion immediately doubles the addressable market for Senhance in the US and validates our regulatory strategy to successfully add to our indications for use,. These expanded procedures are commonly performed at over 95% of hospitals in the United States. We believe this indication expansion will significantly increase the applicability of Senhance to more institutions, particularly those with a busy general surgery practice."

Given the news, it isn't hard to figure out why investors are having a great day.

Now what

The news out of TransEnterix has been extremely positive in recent months. A few weeks ago we learned that the company sold five Senhance systems so far in 2018, which I think is very impressive. Last week the company announced that it secured a $40 million debt financing agreement. The move extended the company's runway in a non-dilutive manner. When adding in today's regulatory news, it is understandable why shares have almost doubled since the start of the year.

TRXC Chart

TRXC data by YCharts

Will this label expansion claim help the company to win over some of the naysayers and accelerate system sales? That question remains an unknown, so I continue to believe that taking a wait-and-see approach to this stock makes the most sense. However, there's no doubt that the company is making progress to improve its financial position and increase the commercial viability of its product. If the company can continue to execute against its promises, then it won't be long before I officially count myself as a bull.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Asensus Surgical, Inc. Stock Quote
Asensus Surgical, Inc.
ASXC
$0.38 (-4.04%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
316%
 
S&P 500 Returns
112%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 07/02/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.